Stock listing

0IFK Stock Price, News, Filings & Events — Editas Medicine, Inc.

Selected listing: 0IFK · LSE · USD · GB

This page tracks Editas Medicine, Inc.'s 0IFK:LSE listing on LSE in USD for GB, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 0IFK:LSE. 0IFK:LSE is the stock-level entry point for investors researching Editas Medicine, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. The company's market capitalization is approximately $399 million. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.

0IFK:LSEUSDGBUpdated September 11, 2026
Editas Medicine, Inc. logo
Ticker
0IFK:LSE
Asset type
Stock
Market cap
$414.7M
Sector
Health Technology
Industry
Biotechnology
Exchange
LSE
Currency
USD

Editas Medicine, Inc. 0IFK:LSE stock context

This page tracks Editas Medicine, Inc.'s 0IFK:LSE listing on LSE in USD for GB, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following 0IFK:LSE. 0IFK:LSE is the stock-level entry point for investors researching Editas Medicine, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Editas Medicine, Inc. is a public biotechnology company based in America, focused on developing transformative genomic medicines. The company's market capitalization is approximately $399 million. Editas is engaged in advancing its proprietary gene-editing technology to address various genetic diseases.

Latest news from Editas Medicine, Inc.

All Editas Medicine, Inc. news →

Editas Medicine, Inc. earnings calls

Research Editas Medicine, Inc.

Alternate listings